Stock comparison
Drugs Made In America Acquisition II Corp. Ordinary Shares
MSCI
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
DMII
Drugs Made In America Acquisition II Corp. Ordinary Shares
Market cap
$528.3M
Sector
Financials
MSCI
MSCI
Market cap
$42.85B
Sector
Financials
Overall winner
MSCI MSCI
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | DMII | MSCI | Winner |
|---|---|---|---|
| Warren Buffett | 16F | 80A | MSCI |
| Benjamin Graham | 5F | 71B | MSCI |
| Philip Fisher | 15F | 82A | MSCI |
| Peter Lynch | 10F | 70B | MSCI |
| Joel Greenblatt | 33F | 80A | MSCI |
| Charlie Munger | 8F | 87C | MSCI |
| Terry Smith | 13F | 88C | MSCI |
Side-by-side metrics
| Metric | DMII | MSCI |
|---|---|---|
| Market cap | $528.3M | $42.85B |
| P/E (TTM) | 1.2x | 31.2x |
| EV/EBIT | - | 27.5x |
| ROIC (TTM) | -0.26% | 38.53% |
| Gross margin | 0.0% | 82.86% |
| Net margin | 0.0% | 40.74% |
| Revenue CAGR 5y | - | 11.29% |
| EPS CAGR 5y | - | 15.35% |
| Debt / Equity | - | - |
| Dividend yield | 0.0% | 1.37% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
DMII leads on
- EV/EBIT-vs 27.5x+114%
- P/E (TTM)1.2xvs 31.2x+96%
MSCI leads on
- ROIC (TTM)38.53%vs -0.26%+101%
- Gross margin82.86%vs 0.0%+100%
- Net margin40.74%vs 0.0%+100%
- Debt / Equity-vs -+100%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.